TPF诱导化疗联合术后放疗治疗口腔鳞癌的疗效及对ING4、Annexin A1的影响

doi:10.19438/j.cjoms.2018.05.010

中国口腔颌面外科杂志 ›› 2018, Vol. 16 ›› Issue (5): 436-440.doi: 10.19438/j.cjoms.2018.05.010

TPF诱导化疗联合术后放疗治疗口腔鳞癌的疗效及对ING4、Annexin A1的影响

李怀奇, 武和明, 丁旭, 叶金海, 吴煜农

南京医科大学口腔疾病研究江苏省重点实验室,南京医科大学附属口腔医院口腔颌面外科,江苏南京 210029

收稿日期:2017-04-28 出版日期:2018-09-20 发布日期:2018-11-06
通讯作者: 武和明,E-mail：whmz2002@aliyun.com
作者简介:李怀奇（1977-）,男,硕士,主治医师,E-mail：lihuaiqi781214@sohu.com
基金资助:
江苏高校优势学科建设工程资助项目（2014-37）

Effect of TPF induced chemotherapy combined with postoperative radiotherapy on oral squamous cell carcinoma and its impact on expression of ING4 and Annexin A1

LI Huai-qi, WU He-ming, DING Xu, YE Jin-hai, WU Yu-nong

Key Laboratory of Oral Diseases of Jiangsu Province, Department of Oral and Maxillofacial Surgery, Stomatological Hospital of Nanjing Medical University, Nanjing Medical University. Nanjing 210029, Jiangsu Province, China

Received:2017-04-28 Online:2018-09-20 Published:2018-11-06

摘要/Abstract

摘要： 目的: 观察TPF诱导化疗联合术后放疗治疗口腔鳞癌的临床疗效,及其对ING4、Annexin A1的影响。方法: 选择2013年6月—2015年6月收治的口腔鳞癌患者146例,按照随机数字表法分为观察组和对照组,每组各73例。观察组给予TPF诱导化疗+手术切除+术后放疗,对照组给予手术切除加术后放疗。比较2组患者的临床疗效,检测治疗前、后2组患者ING4和Annexin A1的表达水平,记录2组患者不良反应的发生率和1年、2年生存率。采用SPSS 19.0软件包对数据进行统计学分析。结果: 观察组和对照组的总缓解率分别为88.41%和58.57%,观察组的总缓解率显著高于对照组（χ²=23.690,P=0.000）。治疗前,2组患者ING4的阳性表达率和Annexin A1相对表达水平相当（P>0.05）。治疗后,2组患者的ING4的阳性表达率均显著升高,Annexin A1相对表达水平均下降,但观察组的改变幅度显著高于对照组（P<0.05）。观察组的1年及2年生存率均显著高于对照组（P<0.05）。观察组的恶心、呕吐、口腔黏膜受损、白细胞降低及放射性皮疹等不良反应发生率均显著高于对照组（P<0.05）。结论: TPF诱导化疗联合术后放疗治疗口腔鳞癌能够有效提高临床疗效和短期生存率,其作用通过升高ING4表达水平、降低Annexin A1表达水平,促进细胞凋亡而实现。

关键词: 口腔鳞癌, TPF诱导化疗, 术后放疗, ING4, Annexin A1

Abstract: PURPOSE: To observe the clinical effect of TPF induced chemotherapy combined with postoperative radiotherapy on oral squamous cell carcinoma (OSCC) and its impact on expression of ING4 and Annexin A1. METHODS: A total of 146 patients with oral squamous cell carcinoma (OSCC) treated from June 2013 to June 2015 in our hospital were selected. According to random digital table, the patients were divided into observation group and control group with 73 cases in each group. Patients in observation group were treated with TPF induced chemotherapy and postoperative radiotherapy; while patients in the control group were treated with surgical resection plus postoperative radiotherapy. The clinical efficacy of the two groups was observed and compared. The expression of ING4 and Annexin A1 in the two groups before and after treatment was detected. The incidence of adverse reactions, 1- and 2-year survival rates were recorded and compared between the two groups. SPSS19.0 software package was used for statistical analysis. RESULTS: The total remission rates of the observation group and the control group were 88.41% and 58.57%, respectively. The total remission rate of the observation group was significantly higher than that of the control group (χ²=23.690, P=0.000). Before treatment, the positive expression rate of ING4 and the relative expression level of Annexin A1 were similar between the two groups (P>0.05). After treatment, the positive expression rate of ING4 in the observation group was significantly higher than that of the control group (P<0.05), and the relative expression level of Annexin A1 in the observation group was significantly lower than that of the control group (P<0.05). The 1- and 2-year survival rates in the observation group were significantly higher than those in the control group (P<0.05). The incidence of nausea, vomiting, oral mucosa damage, leucopenia and radionuclide rash in the observation group were significantly higher than those in the control group (P<0.05). CONCLUSIONS: TPF induced chemotherapy combined with postoperative radiotherapy can effectively improve the clinical efficacy and short-term survival rate of patients with oral squamous cell carcinoma. The possible mechanisms involved increasing the expression of ING4, reducing the expression of Annexin A1 and promoting apoptosis.

Key words: Oral squamous cell carcinoma, TPF induced chemotherapy, Postoperative radiotherapy, ING4, Annexin A1

中图分类号:

R739.8

李怀奇, 武和明, 丁旭, 叶金海, 吴煜农. TPF诱导化疗联合术后放疗治疗口腔鳞癌的疗效及对ING4、Annexin A1的影响[J]. 中国口腔颌面外科杂志, 2018, 16(5): 436-440.

LI Huai-qi, WU He-ming, DING Xu, YE Jin-hai, WU Yu-nong. Effect of TPF induced chemotherapy combined with postoperative radiotherapy on oral squamous cell carcinoma and its impact on expression of ING4 and Annexin A1[J]. China J Oral Maxillofac Surg, 2018, 16(5): 436-440.

参考文献

[1] Li C, Li Q, Cai Y, et al.Overexpression of angiopoietin 2 promotes the formation of oral squamous cell carcinoma by increasing epithelial-mesenchymal transition-induced angiogenesis[J]. Cancer Gene Ther, 2016, 23(9): 295-302.
[2] Alterio D, Rocca M C, Russell-Edu W, et al.Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology[J]. Med Oncol, 2017, 34(5): 86-91.
[3] Mao ZL, He SB, Sheng WH, et al.Adenovirus-mediated ING4 expression reduces multidrug resistance of human gastric carcinoma cells in vitro and in vivo[J]. Oncol Rep, 2013, 30(5): 218-225.
[4] Álvarez-Teijeiro S, Menéndez ST, Villaronga MÁ, et al.Annexin A1 down-regulation in head and neck squamous cell carcinoma is mediated via transcriptional control with direct involvement of miR-196a/b[J]. Sci Rep, 2017, 7(1): 6790-6796.
[5] Massano J, Regateiro FS, Januário G, et al.Oral squamous cell carcinoma: review of prognostic and predictive factors[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2006, 102(1): 67-70.
[6] 陈晓涛, 刘照永, 杨敏. 2123例口腔颌面部肿瘤统计分析[J]. 新疆医科大学学报, 2014, 37(6): 740-743.
[7] Koskinen SK, Niemi PT, Ekfors TO, et al.Glomus tumor of the trachea[J]. Eur Radiol, 1998, 8(3): 364-366.
[8] Miyashita H, Mori S, Motegi K, et al.Pin1 is overexpressed in oral squamous cell carcinoma and its levels correlate with cyclin D1 overexpression[J]. Oncol Rep, 2003, 10(2): 455-461.
[9] Specenier PM, Remenar E, Buter J, et al.TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial[J]. Ann Oncol, 2017, 28(9): 2219-2224.
[10] Ogura T, Tanaka Y, Tamaki H, et al.Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells[J]. Int J Oncol, 2016, 48(6): 2330-2338.
[11] Rodríguez-Vázquez N, García-Fandiño R, Aldegunde MJ, et al.cis-platinum complex encapsulated in self-assembling cyclic peptide dimmers[J]. Org Lett, 2017, 19(10): 2560-2563.
[12] Scheithauer W, Mckendrick J, Begbie S, et al.Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase Ⅲ trial[J]. Ann Oncol, 2003, 14(12): 1735-1741.
[13] 张冰, 房居高, 张树荣, 等. 局部晚期喉咽鳞状细胞癌紫杉醇+顺铂+氟尿嘧啶方案诱导化疗的近期疗效观察[J]. 中国耳鼻咽喉头颈外科, 2015, 22(11): 566-568.
[14] 陆建荣, 张玲, 班华杰, 等. TOF方案诱导化疗口腔鳞癌的近期疗效及不良反应观察[J]. 右江医学, 2017, 45(1): 20-23.
[15] 杨媛媛, 周诺, 蒙宁, 等. 中晚期口腔鳞状细胞癌术前多西他赛联合顺铂及5-氟尿嘧啶诱导化疗的安全性研究[J]. 广西医学, 2015, 37(11): 1550-1552.
[16] 钱莉, 董晓荣, 李贵玲, 等. 胃癌组织ING4和HIF-1α及VEGF表达的相关性分析[J]. 中华肿瘤防治杂志, 2012, 19(8): 600-603.
[17] 张金山, 朱宗恒, 王钢胜, 等. 乳腺癌组织中ING4、HIF-1α和HIF-2α表达及与肿瘤微血管新生的关系[J]. 安徽医药, 2017, 21(5): 847-851.
[18] 乔金科, 朱东旺, 杨筱, 等. 膜联蛋白A1与口腔鳞癌细胞增殖的关系[J]. 中国口腔颌面外科杂志, 2015, 13(4): 303-307.

TPF诱导化疗联合术后放疗治疗口腔鳞癌的疗效及对ING4、Annexin A1的影响

Effect of TPF induced chemotherapy combined with postoperative radiotherapy on oral squamous cell carcinoma and its impact on expression of ING4 and Annexin A1

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈华, 李婧, 罗梅. 红景天甙通过NRF2/KEAP1通路对口腔鳞癌细胞生长的影响[J]. 中国口腔颌面外科杂志, 2024, 22(5): 424-429.
[2]	黄灿, 罗涛, 孙宇. 改良衰弱评估对行口腔鳞癌皮瓣重建术老年患者术后并发症的预测价值[J]. 中国口腔颌面外科杂志, 2024, 22(4): 373-377.
[3]	李华盛, 周迪, 韩楠男, 严明, 阮敏. 石蒜碱通过降解SCAP蛋白抑制口腔鳞癌细胞增殖与侵袭的实验研究[J]. 中国口腔颌面外科杂志, 2024, 22(1): 29-35.
[4]	刘恒, 李永頔, 尹鑫海, 段晓峰. 铁蛋白重链1在头颈鳞癌中的表达及对口腔鳞癌增殖、迁移、侵袭的影响[J]. 中国口腔颌面外科杂志, 2023, 21(6): 529-537.
[5]	赵铜超, 梁思源, 周知航, 朱方兴, 琚梧桐, 谈亦然, 刘莹, 钟来平. BMI与局部晚期口腔鳞癌患者预后及诱导化疗效果的相关性研究[J]. 中国口腔颌面外科杂志, 2023, 21(6): 559-565.
[6]	朱方兴, 周知航, 琚梧桐, 谈亦然, 刘莹, 钟来平, 赵铜超. 基于基线期dNLR水平对局部晚期口腔鳞癌患者生存的预后预测—10年临床回顾[J]. 中国口腔颌面外科杂志, 2023, 21(6): 566-571.
[7]	靳能皓, 田瑜, 朱亮, 乔波, 李粮博, 张海钟, 张蕾. PD-L1及肿瘤免疫微环境对预测口腔鳞癌新辅助治疗效果的意义[J]. 中国口腔颌面外科杂志, 2023, 21(6): 572-578.
[8]	吴朱昊, 张兴伟, 孙亚威, 李子慧, 陈欣, 蒲玉梅, 胡勤刚, 董迎春, 孙国文. ICG荧光导航技术在晚期口腔鳞癌救治性手术中的应用[J]. 中国口腔颌面外科杂志, 2023, 21(3): 248-252.
[9]	刘恒, 段晓峰. 铁自噬及相关基因NCOA4、FTH1在口腔鳞癌中的研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(1): 87-91.
[10]	季萍萍, 李莉, 吴奕帆, 侯黎莉. 经皮穴位电刺激防治口腔鳞癌患者诱导化疗后骨髓抑制的效果观察[J]. 中国口腔颌面外科杂志, 2022, 20(5): 455-460.
[11]	许刚, 宋其义, 蒋卫东, 刘景秀. 水通道蛋白3在口腔鳞癌中的表达及临床意义[J]. 中国口腔颌面外科杂志, 2022, 20(5): 478-482.
[12]	赵小妹, 夏荣辉, 钟来平, 朱东旺, 张志愿. Nrf2对口腔鳞癌患者TPF诱导化疗效果的影响[J]. 中国口腔颌面外科杂志, 2022, 20(4): 366-370.
[13]	张益益, 杨玥怡, 琚梧桐, 钟来平. 局部晚期口腔鳞癌新辅助免疫靶向治疗2例及文献复习[J]. 中国口腔颌面外科杂志, 2022, 20(4): 413-416.
[14]	魏东亮, 李智, 鞠侯雨, 吴云腾, 郭伟, 任国欣. EGFR靶向药物对口腔癌疼痛缓解作用的机制探讨[J]. 中国口腔颌面外科杂志, 2022, 20(3): 219-224.
[15]	孙大为, 张云, 朱勇. shRNA干扰Rce1基因表达对口腔鳞癌细胞放射敏感性的影响[J]. 中国口腔颌面外科杂志, 2022, 20(2): 123-128.